大脑转化 AAV 传递平台-猫眼课题宝

大脑转化 AAV 传递平台

批准号：

8513428

负责人：

Krystof S Bankiewicz

金额：

$56.41万

依托单位：

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

依托单位国家：

美国

项目类别：

财政年份：

2011

资助国家：

美国

项目状态：

已结题

起止时间：

2011-08-01 至 2016-07-31

来源：

https://reporter.nih.gov/project-details/8513428

关键词：

Address Axonal Transport Behavior Brain Brain Stem Brain region Cannulas Cellular Tropism Clinic Clinical Clinical Trials Communities Corpus striatum structure Development Disease Employee Strikes FDA approved Gene Delivery Gene Transduction Agent Gray unit of radiation dose Human Image Immune response Infusion procedures Investments Island Magnetic Resonance Imaging Monitor Movement Multiple Sclerosis Nature Neurologic Neurons Neurosurgeon Oligodendroglia Patients Performance Primates Procedures Property Protocols documentation Relative (related person)Research Personnel Resources Safety Scientist Serotyping Specificity Structure System Techniques Technology Thalamic structure Therapeutic Therapeutic Agents Tracer Viral Vector adeno-associated viral vector anterograde transport base clinically relevant design empowered gene therapy gray matter improved in vivo millimeter nervous system disorder neurosurgery nonhuman primate programs putamen response transgene expression vector white matter

项目摘要

项目成果

Krystof S Bankiewicz的其他基金

相似基金

相关文献

中文摘要

翻译

描述(由申请人提供)：为了将神经学基因治疗应用于临床，迫切需要提高我们对基因传递载体的理解，特别是在直接脑传递后的分布和安全性。虽然AAV2目前主导着临床开发，但替代AAV血清型可能更适合某些应用。最近改变游戏规则的图像引导递送技术的发展提供了在直接脑递送后准确比较不同载体的机会。因此，我们旨在研究AAV1、AAV2、AAV5、AAV8和AAV9在非人类灵长类动物(NHP)大脑灰质或白质结构中的分布和免疫应答。这种对AAV载体的深入评估将为研究人员为特定的神经学应用选择特定的载体提供科学依据。

英文摘要

DESCRIPTION (provided by applicant): To advance neurological gene therapy applications into the clinic there is an urgent need to improve our understanding of gene delivery vectors, with particular emphasis on distribution and safety after direct brain delivery. While AAV2 currently dominates clinical development, alternative AAV serotypes may be better suited for some applications. The recent game-changing development of image-guided delivery techniques provides opportunity to accurately compare different vectors after direct brain delivery. Accordingly we aim to investigate the distribution and immune responses of 5 AAV serotypes (AAV1, 2, 5, 8 and 9) after confined delivery to grey or white matter structures in the non-human primate (NHP) brain. This in-depth assessment of AAV vectors will provide investigators with scientific rational for selecting a specific vector for a particular neurological application.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文